MindMed’s Jr Rahn On Restructuring How We Treat Mental Health (And why he founded MindMed)

Today's episode for you focuses on why C-O FOUNDER and CEO JR Rahn founded Mindmed and on Reconstructing how we treat mental health in America. MindMed, (MMED) on the Canadian NEO Stock exchange and (MMEDF) on the American Over the counter market has been experiencing a pull back lately. Remember what I said before: MindMed should be looked as a long term investment and is not for investors with weak stomachs! During his recent appearance on Context 360 with Kevin O'Leary, MindMed's Co-Ceo Jr Rahn made a sober prediction that the mental health crisis will only get worse. -automation, sped up by the Rona virus, will depend our crisis of identity, and cause millions more to suffer. If we do nothing now, soon we could be living in a very dark world -to reiterate a couple alarming stats; 40% have has a mental health incident or have addiction and 11% have considered committing suicide. This is terrifying, and only going to get worse. MindMed was founded with the vision to find a solution or rather multiple solutions to these mental problems. If successful, the company stands to take the biotech industry by storm and we, as psychedelic investors, will reap the returns. https://www.youtube.com/watch?v=mNfq6eEUT7Q&t=459s&ab_channel=ContextLive Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF
neon mind

Psychedelic Business News Spotlight: January 29, 2021

This week in psychedelic business news, Psyence Group's psilocybin harvest, NeonMind's new CEO, and Mydecine sponsors new research.

How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)

Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock. It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong. We will cover the very real risks involved in investing in MindMed such as: 1. The possibility of MindMed's medicines being inefficacious - Whether of not MMED's clinical trials succeed 2.MindMed's incertain long term profitability - Can the company scale production and training protocols? 3.MindMed Stock volatility - MindMed's market cap - Future short interests MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF) MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own

Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines)

What's up Psychedelic Investors? In today's episode entitled :Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF'S Timelines), we discuss a correction I have to make to my MindMed (MMED / MMEDF) coverage regarding their clinical trials treating addiction with 18MC, and ADHD with LSD microdoses. The start dates for these phase 2a trials have been postponed until the third quarter of 2021, and have not yet started. MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF

More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

Today we'll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O'Leary comments) Today's episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021. We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out. So in this episode we are briefly going to run through them. So what else can MindMed and MMED/MMEDF investors expect this year? 1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK) -When will it launch? -In what manner will it affect MindMed -And how much it will influence MindMed's stock price 2. Atai Life Sciences expected IPO how that'll affect MindMed - How will the IPO of another big rival will affect MMED/MMEDF? 3. Potential catalyst of Partnerships, Mergers and Acquisitions -Coming directly from an Interview with JR Rahn and Kevin O’Leary Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF
Psychedelic Business News Spotlight: January 22, 2021

Psychedelic Business News Spotlight: January 22, 2021

This week in psychedelic industry news: the first psychedelic stock index, new products, mergers, and funds.

Daniel Carcillo’s Wesana Health Raises $4 Million to Expand Psychedelic Research

,
Wesana Health, founded by former NHL star Daniel Carcillo, has raised $4 million to continue its psychedelic research for traumatic brain injuries.

MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF)

In today's episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF). 2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year. But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars? In this episode, we are going to talk about several catalysts to look out for 1. MindMed's Nasdaq uplisting - When to expect MindMed to join the Nasdaq? - Is MindMed's uplisting a sure thing? -What will happen to MindMed stock if/when the company gets uplisted? 2. Clinical trials wrapping up, and data being released by MindMed - Important dates MindMed investors should circle in their calendars 3. MindMed's quarter end financial reporting 4. MindMed conference calls Unknown Catalysts for Mindmed: 1. Clinical trials expansions 2. Financial agreements ** Also, on the 20th of January, Kevin O'Leary and Jr Rahn went live discussing MindMed. For those who haven't seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF

Is MindMed Expanding to PSILOCYBIN? (BIG MMED / MMEDF Stock NEWS)

In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin. Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled "MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience". MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer. Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project And that project will be researching the effects of Psilocybin So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS). So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up. MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine.. So does this mean that MindMed's hiring decision is related to the company's plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed's potential product pipeline as well as the MindMed stock. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF

MindMed Expands MICRODOSING trials (BIG MMED/MMEDF stock UPDATE)

In today's episode "MindMed Expands Microdosing Trials", we'll discuss a Big MindMed Stock Update. On January 12th, MindMed ticker symbol (NEO: MMED ) and (OTC:MMEDF) put out a Press Release entitled MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers. In other words, MindMed is expanding its LSD microdosing studies from just looking at how they can help those with adult ADHD, to how they could affect a more general population. This is BIG news the MindMed team and us shareholders. As I mentioned in one of our previous episodes : "Why I'm More Excited About MindMed's 18-MC than its LSD treatments", MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. And If these trials come back successful, it'll be the beginning of more LSD microdosing studies for MindMed. In this episode, we will do three things: 1:We'll read the Press Release and discuss what it means, in layman's terms 2: We'll enter the Speculation Zone to discuss the potential effects of this move 3: We'll discuss how this expansion affects MindMed stock as an investment So, what does this all mean for investors? Can we assume that MindMed’s LSD microdosing to treat ADHD trial is going well? This, even without the new trials, would be very good news for us long term investors. Moreover, this new study shows that MindMed is continuing to expand their potential product pipeline which will also look great for the MMED/ MMEDF Stock. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF